These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30500939)

  • 1. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
    Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
    Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
    Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
    Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
    J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
    Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
    Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
    Suekane S; Yutani S; Yamada A; Sasada T; Matsueda S; Takamori S; Toh U; Kawano K; Yoshiyama K; Sakamoto S; Sugawara S; Komatsu N; Yamada T; Naito M; Terasaki M; Mine T; Itoh K; Shichijo S; Noguchi M
    Int J Oncol; 2020 Jun; 56(6):1479-1489. PubMed ID: 32236612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
    Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
    Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
    Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
    Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
    Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
    Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
    Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
    Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
    Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
    Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
    Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
    Suekane S; Ueda K; Nishihara K; Sasada T; Yamashita T; Koga N; Yutani S; Shichijo S; Itoh K; Igawa T; Noguchi M
    Cancer Sci; 2017 Dec; 108(12):2430-2437. PubMed ID: 28940789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
    Bloch O; Crane CA; Fuks Y; Kaur R; Aghi MK; Berger MS; Butowski NA; Chang SM; Clarke JL; McDermott MW; Prados MD; Sloan AE; Bruce JN; Parsa AT
    Neuro Oncol; 2014 Jan; 16(2):274-9. PubMed ID: 24335700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.